Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Structure Therapeutics Inc. - American Depositary Shares
(NQ:
GPCR
)
39.79
+0.64 (+1.63%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Structure Therapeutics Inc. - American Depositary Shares
< Previous
1
2
3
4
Next >
3 Promising Biotech Stocks for the Long-Term: August 2024
August 13, 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
Via
InvestorPlace
GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q2 2024
August 09, 2024
GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Structure Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
August 08, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
3 Biotech Stocks That Could Make Your Summer Unforgettable
July 30, 2024
If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.
Via
InvestorPlace
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
July 22, 2024
Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.
Via
The Motley Fool
Peering Into Structure Therapeutics's Recent Short Interest
July 15, 2024
Via
Benzinga
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
July 19, 2024
The Nasdaq tumbled amid chip woes.
Via
Investor's Business Daily
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 17, 2024
Via
Benzinga
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
July 17, 2024
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest...
Via
Benzinga
ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
July 17, 2024
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
July 12, 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment.
Via
InvestorPlace
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
July 09, 2024
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been
Via
MarketBeat
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
July 03, 2024
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases
Via
MarketBeat
Exposures
Product Safety
Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
July 02, 2024
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy
Via
MarketBeat
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
June 28, 2024
With global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.
Via
InvestorPlace
Could Structure Therapeutics Become the Next Novo Nordisk?
June 17, 2024
Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
Via
The Motley Fool
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
June 14, 2024
The company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
Via
Investor's Business Daily
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
June 11, 2024
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
Via
The Motley Fool
Skye Bioscience Pivots To Obesity After Glaucoma Flop; Shares Plummet
June 10, 2024
The company is focusing on obesity treatment after its glaucoma drug failed.
Via
Investor's Business Daily
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
June 09, 2024
Structure Therapeutics has a long way to go before beating Wegovy.
Via
The Motley Fool
Top Names Performance Update - Saturday, June 8
June 08, 2024
I usually show the performance of the top names cohort from six months earlier, but we didn’t have the full, six-month performance of our Dec. 7 top names cohort yet, so here is a stand-alone...
Via
Talk Markets
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
June 08, 2024
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...
Via
Talk Markets
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
June 07, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering
June 05, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
June 04, 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate
Via
InvestorPlace
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
June 03, 2024
From
Structure Therapeutics Inc.
Via
GlobeNewswire
Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
June 03, 2024
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
Via
Benzinga
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
June 03, 2024
Via
Benzinga
Structure Therapeutics Stock Skyrockets To Six-Month High On Compelling Weight-Loss Drug Results
June 03, 2024
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
June 03, 2024
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.